Coronavirus Uncategorized

Russia’s Sputnik-V COVID-19 Vaccine Is Decline To Test By India

Setback For Russia As India Decline To Test

Russia’s Sputnik-V COVID-19 Vaccine Is Decline To Test By India: India before doing the full trial step back the proposal from Dr Reddy’s Laboratories while evaluating Russia’s COVID-19 vaccine in a large study as Drug Regulator has suggested for a small problem.


Sputnik V

India proved to be a setback for Russia while pushing back its efforts to win approval for the vaccine in the country.

While the Russian Direct Investment Fund and Dr. Reddys Laboratries both in partnership decided to distribute vaccine in India. India’s rising case of COVID 19 seems to overtake the United States over the next several weeks as the country with the world’s largest number of cases.

About Sputnik-V

Russia made the first coronavirus vaccine and named it Sputnik-V. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund develop the vaccine. It is a vector-based and registered on 11 August.

India’s expert panel of the Central Drugs Standard Control Organisation (CDSCO) took a review from Dr. Reddy’s Laboratories in order to submit a revised protocol for conducting both phase 2 and phase 3 human clinical trials for the Russian vaccine against Covid-19, Sputnik V.

If these trials turn successful, Russia has ready to supply 100 million doses to India. This vaccine is developed as a two-dose vaccine using two human recombinant adenovirus vectors namely rAd5 and rAd26 which is known to cause respiratory infection.

Russia test Sputnik-V

There were several vaccines were made using human adenovirus but none of them have been commercially approved. But Russia Sputnik- V  gots its approval. The vaccine trial is on controversies. As the Russian government registered it as a vaccine without any proper trial. Russia conducted only Phase I and Phase II trials which rarely involve 76 participants.

Moreover, some of the countries were also a little inconsistent during the vaccine trial of Sputnik-6. So, Indian medical experts suggested India to conduct a phase II trial of Sputnik-V for further safety and security.

About the author

Muskan Gupta